Skip to main content
PMC home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1983 Feb;15(2):253–258. doi: 10.1111/j.1365-2125.1983.tb01494.x

Studies on the pharmacokinetics of chlorambucil and prednimustine in man.

D R Newell, A H Calvert, K R Harrap, T J McElwain
PMCID: PMC1427847  PMID: 6849759

Abstract

1 Chlorambucil (10 mg) and prednimustine (20 mg), the prednisolone ester of chlorambucil, were administered orally on separate occasions to six patients. 2 Chlorambucil was rapidly absorbed such that the parent compound was observed in the plasma 30 min after administration. 3 A preliminary comparison of chlorambucil levels following oral and intravenous administration, and after repeat oral dosage indicated that chlorambucil was well (greater than 70%) and consistently absorbed. 4 Following prednimustine no parent drug or alkylating metabolites (chlorambucil or phenyl acetic mustard) could be detected in the plasma. 5 In studies with intravenously administered chlorambucil plasma levels of the parent drug were described by a two-compartment open model with first-order kinetics. Significant levels of the cytotoxic metabolite phenyl acetic mustard were detected. 6 It is concluded that: a. the bioavailability of orally administered prednimustine is much lower than that of chlorambucil. Thus the use of prednimustine in routine combination therapy is not recommended. b. due to the lower therapeutic index of phenyl acetic mustard in experimental systems, the production of this metabolite in man may be disadvantageous. Thus research aimed at producing chlorambucil analogues, which cannot be metabolised, seems justified.

Full text

PDF
253

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Alberts D. S., Chang S. Y., Chen H. S., Larcom B. J., Evans T. L. Comparative pharmacokinetics of chlorambucil and melphalan in man. Recent Results Cancer Res. 1980;74:124–131. doi: 10.1007/978-3-642-81488-4_16. [DOI] [PubMed] [Google Scholar]
  2. Farmer P. B., Foster A. B., Jarman M., Newell D. R., Oddy M. R., Kiburis J. H. The metabolism of deuterated analogues of chlorambucil by the rat. Chem Biol Interact. 1979 Dec;28(2-3):211–224. doi: 10.1016/0009-2797(79)90162-5. [DOI] [PubMed] [Google Scholar]
  3. Godenèche D., Madelmont J. C., Moreau M. F., Plagne R., Meyniel G. Comparative physico-chemical properties, biological effects, and disposition in mice of four nitrogen mustards. Cancer Chemother Pharmacol. 1980;5(1):1–9. doi: 10.1007/BF00578555. [DOI] [PubMed] [Google Scholar]
  4. Kaye S. B., Juttner C. A., Smith I. E., Barrett A., Austin D. E., Peckham M. J., McElwain T. J. Three years' experience with Ch1VPP (a combination of drugs of low toxicity) for the treatment of Hodgkin's disease. Br J Cancer. 1979 Feb;39(2):168–174. doi: 10.1038/bjc.1979.27. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Kirdani R. Y., Murphy G. P., Sandberg A. A. Some metabolic aspects of a nitrogen mustard of prednisolone. Oncology. 1978;35(2):47–53. doi: 10.1159/000225254. [DOI] [PubMed] [Google Scholar]
  6. Könyves I., Nordenskjöld B., Forshell G. P., de Schryver A., Westerberg-Larsson H. Preliminary clinical and absorption studies with prednimustine in patients with mammary carcinoma. Eur J Cancer. 1975 Dec;11(12):841–844. doi: 10.1016/0014-2964(75)90082-1. [DOI] [PubMed] [Google Scholar]
  7. Leff P., Bardsley W. G. Pharmacokinetics of chlorambucil in ovarian carcinoma using a new HPLC assay. Biochem Pharmacol. 1979 Apr 15;28(8):1289–1292. doi: 10.1016/0006-2952(79)90426-x. [DOI] [PubMed] [Google Scholar]
  8. McElwain T. J., Hedley D. W., Gordon M. Y., Jarman M., Millar J. L., Pritchard J. High dose melphalan and non-cryopreserved autologous bone marrow treatment of malignant melanoma and neuroblastoma. Exp Hematol. 1979;7 (Suppl 5):360–371. [PubMed] [Google Scholar]
  9. McLean A., Newell D., Baker G. The metabolism of chlorambucil. Biochem Pharmacol. 1976 Oct 15;25(20):2331–2335. doi: 10.1016/0006-2952(76)90019-8. [DOI] [PubMed] [Google Scholar]
  10. McLean A., Woods R. L., Catovsky D., Farmer P. Pharmacokinetics and metabolism of chlorambucil in patients with malignant disease. Cancer Treat Rev. 1979 Jun;6 (Suppl):33–42. doi: 10.1016/s0305-7372(79)80008-0. [DOI] [PubMed] [Google Scholar]
  11. Newell D. R., Hart L. I., Harrap K. R. Estimation of chlorambucil, phenyl acetic mustard and prednimustine in human plasma by high-performance liquid chromatography. J Chromatogr. 1979 Sep 11;164(1):114–119. doi: 10.1016/s0378-4347(00)81580-7. [DOI] [PubMed] [Google Scholar]
  12. Newell D. R., Shepherd C. R., Harrap K. R. The pharmacokinetics of prednimustine and chlorambucil in the rat. Cancer Chemother Pharmacol. 1981;6(1):85–91. doi: 10.1007/BF00253015. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES